zur Navigation zum Inhalt

Pulmologie

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging

11/2016 Consensus of the Austrian Mesothelioma Interest Group (AMIG)

Malignant pleural mesothelioma is a rare malignant disease that in the majority of cases is associated with asbestos exposure. The incidence in Europe is about 20 per million inhabitants and it is increasing worldwide. [...]

Dieser Artikel ist nur für registrierte Mitglieder zugänglich ÖGP 2013 - Kongressjournal downloaden

10/2013 Die Jahrestagung der Österreichischen Gesellschaft für Pneumologie (ÖGP), die vom 24. bis 26. Oktober in Wien stattfindet, hat in diesem Jahr ein sehr an der Praxis orientiertes Programm vorzustellen. Eines der Hauptthemen bei dem Treffen der heimischen Lungenfachärzte ist das metabolische Syndrom - ein Schwerpunkt, der aus Sicht der Pulmologie in Verbindung zur Inneren Medizin diskutiert wird. [...]

Dieser Artikel ist nur für registrierte Mitglieder zugänglich Malignant pleural mesothelioma

11/2016 Dear Reader,

Malignant pleural mesothelioma (MPM) is a rare but highly malignant disease. Although it is not officially accepted as an orphan disease, its low incidence imposes significant difficulties to physicians confronted with affected patients. [...]

Management of malignant pleural mesothelioma – part 3

11/2016 Data from the Austrian Mesothelioma Interest Group (AMIG) database

Background: Malignant pleural mesothelioma (MPM) is a rare but aggressive tumor originating from the pleural cavity with a strong link to previous asbestos exposure. [...]

The neutrophil–lymphocyte ratio as an inflammatory marker in acute exacerbation of COPD

11/2016 To the Editors,

In the last issue of _Wiener Klinische Wochenschrift_, we read the article written by Tanriverdi et al. with great interest. In this well-organized study, the authors compared the diagnostic values of procalcitonin (PCT), C‑reactive protein (CRP), and blood neutrophil/lymphocyte ratio (N/L ratio) levels in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). [...]

Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

11/2016 Background: It was reported that hematological markers of systemic inflammatory response might be prognostic in various cancer types. We aimed to evaluate the platelet/lymphocyte ratio (PLR) as a prognostic factor and its effect on overall survival in non-small cell lung cancer (NSCLC). [...]

Medizin heute

Aktuelle Printausgaben

SCHWERPUNKTE PULMOLOGIE

A-H P-Z